The susceptibility of 513 clinical isolates to doripenem was determined by broth microdilution, agar dilution, and Etest. Overall agreements for Etest and agar dilution MIC values compared to reference broth microdilution at ؎1 log 2 dilution were 88% and 94%, respectively. Etest MIC values demonstrated 98% agreement within ؎2 log 2 dilutions compared to the reference broth microdilution method.
microdilution (BMD), agar dilution, and Etest. As laboratories may use any one or multiple methods, it is of interest to know how MIC results for a drug will compare across methods. In this study the in vitro activity of doripenem against relevant Gram-negative and Gram-positive pathogens was determined by three MIC methods: broth microdilution or the standard reference method, agar dilution, and Etest. The BMD MICs were compared to results from agar dilution and Etest.
(This work was presented in part at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007 [1] . ) Recent clinical isolates (n ϭ 513) were studied from eight major organism groups based on the current groupings in the Clinical and Laboratory Standards Institute (CLSI) M100 supplement (6 Broth microdilution MIC testing followed CLSI methodology (4, 5) using cation-adjusted Mueller-Hinton (MH) broth (Sensititre; Trek Diagnostic Systems, Cleveland, OH) with or without the addition of 3% lysed horse blood (Hardy Diagnostics, Santa Maria, CA). Custom susceptibility panels in the frozen format were obtained from Trek Diagnostic Systems (Cleveland, OH).
Agar dilution MIC testing was performed on MH II agar (BD BBL, Sparks, MD) according to CLSI methodology (4, 5). e The number of staphylococci tested by agar dilution was 97, including 60 S. aureus isolates and 37 coagulase-negative staphylococci.
Organisms were inoculated onto 100-mm agar plates prepared on the day of testing with a replicator (Craft Machine Inc., Chester, PA) that delivered 2 l per spot. For streptococci other than S. pneumoniae, MH agar was supplemented with 5% sheep blood (Hardy Diagnostics, Santa Maria, CA). MIC testing by the doripenem Etest (AB Biodisk, Solna, Sweden) was performed and results were interpreted according to the manufacturer's instructions. MH II agar plates (BD BBL, Sparks, MD) and plates of MH with 5% sheep blood agar (BD BBL, Sparks, MD) were used. Etest MICs were rounded up to the nearest 2-fold dilution in a standard MIC test, and these values were used in comparisons between the Etest and the reference BMD method.
MIC values for isolates to doripenem were generated by BMD, agar dilution, and Etest methods. Agar dilution MICs were not determined for S. pneumoniae, since agar dilution is not a recommended reference method for this organism. The MIC results from agar dilution and Etest were compared to those from the standard reference BMD MIC method. For all isolates, the comparator carbapenem class agent, meropenem, was tested in parallel with doripenem. In testing of the appropriate CLSI QC strains, both doripenem and meropenem performed within acceptable CLSI QC limits (data not shown).
The distribution of doripenem MIC values against Gramnegative and Gram-positive clinical isolates is shown in Table  1 . The isolates were chosen to provide a range of MIC values and were not selected at random. Thus, the number of resistant isolates is higher than those that would be found in a random population. The percentages of doripenem-susceptible clinical isolates were 98% (98/100) for Enterobacteriaceae, 80% (64/80) for P. aeruginosa, and 55% (11/20) for Acinetobacter baumannii based on FDA breakpoints. Of the viridans group streptococci, seven isolates were identified as Streptococcus anginosus group, and of these seven isolates 100% were doripenem susceptible. The FDA susceptible MIC breakpoints for doripenem are Յ0.5 g/ml for Enterobacteriaceae, Յ2 g/ml for P. aeruginosa, Յ1 g/ml for A. baumannii, and Յ0.12 g/ml for S. anginosus group. At this time, susceptible breakpoints for doripenem have not been determined for the other organism groups.
The BMD, agar dilution, and Etest doripenem MIC values are summarized in Table 2 . Among the Gram-negative isolates, all methods yielded a doripenem MIC 90 for Enterobacteriaceae of 0.25 g/ml. For P. aeruginosa the BMD and Etest MIC 90 s were 8 g/ml and the agar dilution MIC 90 was 4 g/ml for doripenem. For A. baumannii, the BMD, Etest, and agar dilution MIC 90 values were 16, Ͼ32, and 8 g/ml, respectively.
Against 49 enterococci, the MIC 50 and MIC 90 were 4 and Ն16 g/ml, respectively, by all three methods. For all staphylococci, the doripenem MIC 90 s were 2 g/ml by BMD and agar dilution and 4 g/ml by Etest. The S. pneumoniae doripenem MIC 90 was 0.5 g/ml by BMD and 2-fold higher by Etest. The MIC 90 for beta-hemolytic streptococci was Յ0.015 g/ml by BMD and agar dilution and 0.03 g/ml by Etest; for viridans group streptococci the MIC 90 was 0.25 g/ml for all test methods.
As doripenem has only susceptible FDA breakpoints, an analysis of very major test errors was conducted for organisms that were defined as nonsusceptible by the reference method, BMD, and categorized as susceptible by agar dilution or Etest. Major errors were determined for organisms that were susceptible by BMD and nonsusceptible by agar dilution or Etest. For the Enterobacteriaceae group, there was one very major error for both agar dilution and Etest methods. Among the P. aeruginosa isolates tested, there was one major error by Etest. For A. baumannii, there were three major errors by both agar dilution and Etest methods. Doripenem MICs for 60% (59/98) of the Enterobacteriaceae, 55% (44/80) of the P. aeruginosa isolates, and 40% (8/20) of the A. baumannii isolates tested were identical for BMD and agar dilution within each group. Among the Gram-positive isolates tested, 50.7% (105/207) had identical MIC results for BMD and agar dilution (Table 3) . Etest and BMD tests had a lower percentage of identical MIC results for many of the organism groups, especially the Enterobacteriaceae, staphylococci, and non-S. pneumoniae isolates. Etest and BMD MICs were identical for only 28% (28/100) of the Enterobacteriaceae, 45% (36/80) of P. aeruginosa isolates, 45% (9/20) of A. baumannii (Table 5) showed Ͼ92% essential agreement (within Ϯ1 log 2 dilution) for Enterobacteriaceae, P. aeruginosa, enterococci, and streptococci that were not S. pneumoniae. A. baumannii and staphylococci demonstrated lower essential agreements (within Ϯ1 log 2 dilution) of 60% and 84.5% for doripenem agar dilution MIC and Etest MIC comparisons, respectively.
The essential agreement (within Ϯ1 log 2 dilution) of doripenem BMD results for all organisms tested compared to agar dilution MICs was 93.6%, and that compared to Etest MICs was 88.1%. A. baumannii and staphylococci demonstrated slightly lower essential agreements (within Ϯ1 log 2 dilution) of 80% and 86.6% by agar dilution and 80% and 64% by Etest, respectively (Tables 3 and 4) . A. baumannii and staphylococci also demonstrated lower essential agreement when Etest results were compared to agar dilution MICs. Organism groups with Ͼ93% essential agreement (within Ϯ1 log 2 dilution) of doripenem BMD and agar dilution MICs were Enterobacteriaceae, P. aeruginosa, enterococci, and viridans group streptococci, and the group with 100% essential agreement (within Ϯ1 log 2 dilution) was beta-hemolytic streptococci. In comparing doripenem BMD to Etest, organism groups with Ͼ92% essential agreement (within Ϯ1 log 2 dilution) of doripenem BMD and agar dilution MICs were Enterobacteriaceae, P. aeruginosa, enterococci, and beta-hemolytic streptococci, and S. pneumoniae showed 100% essential agreement (within Ϯ1 log 2 dilution). Within Ϯ2 log 2 dilutions, the agreements of BMD results for all organisms tested compared to agar dilution and to Etest were 99.3% and 98.2%, respectively.
As commercial methods for susceptibility testing of doripenem are becoming more available, it is important to know how results determined by alternate methods compare to the standard reference method, BMD. This study demonstrated that agar dilution MICs were comparable to BMD MICs with Ն93% essential agreement and that 99% were within Ϯ2 log 2 90 values for all organisms examined, tended to be 1 log 2 dilution higher than the BMD values. This trend was also observed in a previous study with P. aeruginosa isolates at or near the doripenem breakpoint (2 g/ml) (2). In this study, the Etest method performed comparably to the standard reference methods with Ͼ96% of the doripenem MICs within Ϯ2 log 2 dilutions of the BMD and agar dilution methods. Given the overall comparability of these three methods, laboratories should be comfortable in using their method of choice for MIC testing of doripenem. However, it should be recognized that there may be inherent, although sometimes subtle, differences that may occur in MIC testing, depending on the method chosen.
